Unicycive Therapeutics: Addressing a $2.5 Billion Global Market Opportunity in Kidney Disease

A biotech dedicated to developing treatments for unmet medical needs, Unicycive Therapeutics (NASDAQ: UNCY) is currently advancing two programs focused on kidney disease and intends to expand its pipeline to target additional indications within and outside kidney disease. Unicycive is preparing to commercialize and launch its lead therapy, Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease and is continuing development of UNI 494 for treatment of acute kidney injury. Visit UNCYinfo.com to learn more.